ADC Therapeutics (ADCT) Retained Earnings (2019 - 2026)

ADC Therapeutics has disclosed Retained Earnings across 8 years of filings, most recently posting -$802000.0 for Q1 2026.

• Retained Earnings for Q1 2026 came in at -$802000.0, up 99.95% year-over-year; the trailing twelve-month figure through Mar 2026 was -$802000.0 (up 99.95% YoY), and the FY2025 annual result was -$1.6 billion, down 115026.04% from the prior year.
• Retained Earnings came in at -$802000.0 for Q1 2026 at ADC Therapeutics, up from -$1.6 billion in the prior quarter.
• In the past five years, Retained Earnings ranged from a high of -$802000.0 in Q1 2026 to a low of -$1.6 billion in Q4 2025.
• The 5-year median for Retained Earnings is -$1.4 billion (2024), against an average of -$1.2 billion.
• Across the five-year window, Retained Earnings sank 115026.04% in 2025 and surged 99.95% in 2026, its largest moves.
• ADC Therapeutics' Retained Earnings stood at -$1.1 billion in 2022, then retreated by 21.91% to -$1.3 billion in 2023, then surged by 99.89% to -$1.4 million in 2024, then tumbled by 115026.04% to -$1.6 billion in 2025, then jumped by 99.95% to -$802000.0 in 2026.
• The last three Retained Earnings figures came in at -$802000.0 (Q1 2026), -$1.6 billion (Q4 2025), and -$1.6 billion (Q3 2025), per Business Quant data.